BACKGROUND:Methamphetamine (METH) use poses a barrier to antiretroviral therapy (ART) adherence. We evaluated the efficacy of the individualized texting for adherence building (iTAB) intervention among persons living with HIV (PLWH) who meet criteria for METH use disorder. We examined daily associations between ART adherence and text-reported METH use and depressed mood. METHODS: We conducted a single site, 2-arm, 6-week, pilot randomized clinical trial comparing a personalized, bidirectional, text messaging system (iTAB; n = 50) to an active control condition (n = 25). All participants received adherence psychoeducation and daily texts assessing METH use and depressed mood. The iTAB group received personalized daily ART reminder texts. ART adherence was monitored using Medication Event Monitoring System (MEMS) caps. RESULTS:Response rates to daily ART reminder texts were high (79%), with good concordance between MEMS-derived and text-reported ART adherence (p < .001). Intervention groups did not differ in MEMS-derived ART adherence (68% iTAB, 70% active control; p = .68); however, participants in the iTAB group had fewer METH use days (median 14.4 iTAB, 22.0 active control; p = .05). Text-reported METH use, but not depressed mood, was associated with poorer MEMS-derived ART adherence. CONCLUSIONS: High text response rates and good concordance between MEMS-derived and text-reported adherence suggests text messaging is a feasible intervention delivery approach that provides a valid indication of ART adherence. Reductions in METH use among iTAB participants suggest daily health reminders may help attenuate substance use. Further research is needed to substantiate daily text messaging as a harm reduction approach.
RCT Entities:
BACKGROUND:Methamphetamine (METH) use poses a barrier to antiretroviral therapy (ART) adherence. We evaluated the efficacy of the individualized texting for adherence building (iTAB) intervention among persons living with HIV (PLWH) who meet criteria for METH use disorder. We examined daily associations between ART adherence and text-reported METH use and depressed mood. METHODS: We conducted a single site, 2-arm, 6-week, pilot randomized clinical trial comparing a personalized, bidirectional, text messaging system (iTAB; n = 50) to an active control condition (n = 25). All participants received adherence psychoeducation and daily texts assessing METH use and depressed mood. The iTAB group received personalized daily ART reminder texts. ART adherence was monitored using Medication Event Monitoring System (MEMS) caps. RESULTS: Response rates to daily ART reminder texts were high (79%), with good concordance between MEMS-derived and text-reported ART adherence (p < .001). Intervention groups did not differ in MEMS-derived ART adherence (68% iTAB, 70% active control; p = .68); however, participants in the iTAB group had fewer METH use days (median 14.4 iTAB, 22.0 active control; p = .05). Text-reported METH use, but not depressed mood, was associated with poorer MEMS-derived ART adherence. CONCLUSIONS: High text response rates and good concordance between MEMS-derived and text-reported adherence suggests text messaging is a feasible intervention delivery approach that provides a valid indication of ART adherence. Reductions in METH use among iTABparticipants suggest daily health reminders may help attenuate substance use. Further research is needed to substantiate daily text messaging as a harm reduction approach.
Authors: Lynne T Harris; Keren Lehavot; David Huh; Samantha Yard; Michele P Andrasik; Peter J Dunbar; Jane M Simoni Journal: Telemed J E Health Date: 2010-11-18 Impact factor: 3.536
Authors: Joseph Firth; John Torous; Jennifer Nicholas; Rebekah Carney; Abhishek Pratap; Simon Rosenbaum; Jerome Sarris Journal: World Psychiatry Date: 2017-10 Impact factor: 49.548
Authors: David J Moore; Amelia Poquette; Kaitlin B Casaletto; Ben Gouaux; Jessica L Montoya; Carolina Posada; Alexandra S Rooney; Jayraan Badiee; Reena Deutsch; Scott L Letendre; Colin A Depp; Igor Grant; J Hampton Atkinson Journal: AIDS Behav Date: 2015-03
Authors: Charles H Hinkin; David J Hardy; Karen I Mason; Steven A Castellon; Ramani S Durvasula; Mona N Lam; Marta Stefaniak Journal: AIDS Date: 2004-01-01 Impact factor: 4.177
Authors: Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant Journal: J Neurovirol Date: 2010-12-21 Impact factor: 2.643
Authors: Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2020-09-15 Impact factor: 4.147
Authors: Thomas L Patterson; Eileen V Pitpitan; Heather A Pines; Shirley J Semple; Alicia Harvey-Vera; Colin Depp; David J Moore; Gustavo Martinez; M Gudelia Rangel; Steffanie A Strathdee Journal: AIDS Behav Date: 2020-12
Authors: Maulika Kohli; Elizabeth C Pasipanodya; Jessica L Montoya; Maria Marquine; Martin Hoenigl; Vanessa Serrano; Clint Cushman; Rogelio Garcia; John Kua; Verna Gant; Sarah Rojas; David J Moore Journal: JMIR Res Protoc Date: 2020-12-10
Authors: Elizabeth C Pasipanodya; Jessica L Montoya; Caitlin W-M Watson; María J Marquine; Martin Hoenigl; Rogelio Garcia; John Kua; Verna Gant; Joel Trambley; David J Moore Journal: PLoS One Date: 2020-06-09 Impact factor: 3.240